If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 6 of 6
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
Objective
CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Protocol No
C4THERAPEUTICS-CFT7455-1101
Categories
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Mulitple Myeloma (CaMMouflage Trial)
Objective
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With RR MM
Protocol No
CARIBOU-CAMMOUFLAGE-CB-011A-MM
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
Objective
Birtamimab plus SOC vs Placebo plus SOC in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
Protocol No
PROTHENA-NEOD001-301
Categories
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
Objective
Prospective, Observational Study of Participants at Risk for CGVHD
Protocol No
INCYTE-MA-GVHD-401-THRIVE
Categories
MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma - Master-2 Trial
Objective
MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma Patients
Protocol No
UAB-21107-MASTER-2-MM
Categories
A Multisite, Phase II Study of Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone (VICD) Induction in Transplant-Eligible Multiple Myeloma Patients with Renal Insufficiency
Objective
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple
Protocol No
IIT-DHAKAL-VICD-MM
Categories